Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.34 |
| ▸ | HTR2A | P28223 | 4/20 | 0.34 |
| ▸ | HTR2B | P41595 | 4/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | PTGIR | P43119 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26036396 | 1.00 | HTR2C (0.34) | HTR2CHTR2AHTR2BRIPK1KDM1A | |
| SCHEMBL1853880 | 1.00 | HTR2C (0.34) | HTR2CHTR2AHTR2BRIPK1KDM1A | |
| SCHEMBL1853883 | 1.00 | HTR2C (0.34) | HTR2CHTR2AHTR2BRIPK1KDM1A | |
| SCHEMBL9924976 | 0.96 | HTR2C (0.35) | HTR2CHTR2AHTR2BRIPK1KDM1A | |
| SCHEMBL1853160 | 0.96 | HTR2C (0.36) | HTR2CHTR2AHTR2BRIPK1KDM1A | |
| SCHEMBL1853162 | 0.96 | HTR2C (0.36) | HTR2CHTR2AHTR2BRIPK1KDM1A | |
| SCHEMBL26036401 | 0.96 | HTR2C (0.36) | HTR2CHTR2AHTR2BRIPK1KDM1A | |
| SCHEMBL1658516 | 0.95 | HTR2A (0.32) | HTR2CHTR2AHTR2BRIPK1KDM1A | |
| SCHEMBL24170300 | 0.94 | HTR2C (0.37) | HTR2CHTR2AHTR2BRIPK1PDE4B | |
| SCHEMBL12366417 | 0.94 | HTR2C (0.37) | HTR2CHTR2AHTR2BRIPK1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1835009-B1 | NEMATIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY UTILIZING THE SAME | DAINIPPON INK & CHEMICALS (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-7670504-B2 | Nematic liquid crystal composition and liquid crystal display device using the same | DAINIPPON INK & CHEMICALS, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20080111107-A1 | Nematic Liquid Crystal Composition And Liquid Crystal Display Device Using The Same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1835009-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY UTILIZING THE SAME | Dainippon Ink and Chemicals, Incorporated (JP) | 2007-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080111107-A1 | Nematic Liquid Crystal Composition And Liquid Crystal Display Device Using The Same | PIEZO1, KIF20B, VCL | HTR2C 2306/4885HTR2A 1878/4885HTR2B 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.